Parsons Awarded $24 Million Naval Medical Research Command Biodefense Contract
Parsons (NYSE: PSN) has secured a $24 million biological defense research contract from the Naval Medical Research Command (NMRC). The contract includes a one-year base period with four one-year option periods. Parsons will support NMRC's Biological Defense Research Directorate (BDRD) in biological research for rapid infectious disease detection and global disease surveillance.
The company has been performing this work since 2018, providing NMRC with expert scientists in various fields including molecular biology, immunology, serology, bacteriology, laboratory science and management, field collection, field lab detection, outbreak response, reagent production, and assay development.
Parsons (NYSE: PSN) ha ottenuto un contratto da 24 milioni di dollari per la ricerca nella difesa biologica dal Naval Medical Research Command (NMRC). Il contratto prevede un periodo base di un anno con quattro opzioni annuali. Parsons supporterà il Biological Defense Research Directorate (BDRD) del NMRC nella ricerca biologica per la rilevazione rapida delle malattie infettive e la sorveglianza globale delle malattie.
L'azienda sta svolgendo questo lavoro dal 2018, fornendo al NMRC scienziati esperti in vari settori, tra cui biologia molecolare, immunologia, serologia, batteriologia, scienze di laboratorio e gestione, raccolta sul campo, rilevamento in laboratorio sul campo, risposta a focolai, produzione di reagenti e sviluppo di saggi.
Parsons (NYSE: PSN) ha asegurado un contrato de 24 millones de dólares para la investigación en defensa biológica del Naval Medical Research Command (NMRC). El contrato incluye un período base de un año con cuatro períodos de opción de un año. Parsons apoyará al Biological Defense Research Directorate (BDRD) del NMRC en la investigación biológica para la detección rápida de enfermedades infecciosas y la vigilancia global de enfermedades.
La empresa ha estado realizando este trabajo desde 2018, proporcionando al NMRC científicos expertos en diversos campos, incluyendo biología molecular, inmunología, serología, bacteriología, ciencia de laboratorio y gestión, recolección en campo, detección en laboratorio de campo, respuesta a brotes, producción de reactivos y desarrollo de ensayos.
Parsons (NYSE: PSN)는 해군 의학 연구 사령부(NMRC)로부터 2400만 달러 규모의 생물 방어 연구 계약을 체결했습니다. 이 계약은 1년의 기본 기간과 4개의 1년 옵션 기간을 포함합니다. Parsons는 NMRC의 생물 방어 연구국(BDRD)을 지원하여 감염병의 신속한 탐지 및 글로벌 질병 감시에 대한 생물학적 연구를 수행합니다.
회사는 2018년부터 이 작업을 수행하고 있으며, NMRC에 분자 생물학, 면역학, 혈청학, 세균학, 실험실 과학 및 관리, 현장 수집, 현장 실험실 탐지, 발병 대응, 시약 생산 및 분석 개발 등 다양한 분야의 전문 과학자들을 제공하고 있습니다.
Parsons (NYSE: PSN) a obtenu un contrat de recherche en défense biologique d'une valeur de 24 millions de dollars auprès du Naval Medical Research Command (NMRC). Le contrat comprend une période de base d'un an avec quatre périodes d'option d'un an. Parsons soutiendra le Biological Defense Research Directorate (BDRD) du NMRC dans la recherche biologique pour la détection rapide des maladies infectieuses et la surveillance mondiale des maladies.
L'entreprise effectue ce travail depuis 2018, fournissant au NMRC des scientifiques experts dans divers domaines, y compris la biologie moléculaire, l'immunologie, la sérologie, la bactériologie, les sciences de laboratoire et la gestion, la collecte sur le terrain, la détection en laboratoire sur le terrain, la réponse aux épidémies, la production de réactifs et le développement de tests.
Parsons (NYSE: PSN) hat einen Vertrag über 24 Millionen Dollar für die Forschung zur biologischen Verteidigung vom Naval Medical Research Command (NMRC) erhalten. Der Vertrag umfasst einen einjährigen Basiszeitraum mit vier einjährigen Optionszeiträumen. Parsons wird das Biological Defense Research Directorate (BDRD) des NMRC bei biologischen Forschungen zur schnellen Erkennung von Infektionskrankheiten und zur globalen Krankheitsüberwachung unterstützen.
Das Unternehmen führt diese Arbeiten seit 2018 durch und stellt dem NMRC Expertenwissenschaftler aus verschiedenen Bereichen zur Verfügung, darunter Molekularbiologie, Immunologie, Serologie, Bakteriologie, Laborwissenschaften und Management, Feldsammlung, Feldlaborerkennung, Ausbruchsreaktion, Reagenzproduktion und Assay-Entwicklung.
- Secured new $24 million contract with Naval Medical Research Command
- Contract includes potential for 4-year extension through option periods
- Demonstrates continued trust since 2018 in critical government defense work
- None.
Insights
Parsons'
The multi-year structure (one-year base with four one-year options) provides revenue stability in this niche segment where Parsons has established expertise since 2018. Breaking down the potential
What's noteworthy is Parsons' continued positioning in specialized biodefense services supporting critical national security functions. The contract validates their technical capabilities in detecting biological threats and developing surveillance systems to protect military personnel—work requiring specialized scientific talent in molecular biology, immunology, and related fields.
From a competitive standpoint, this award demonstrates Parsons' ability to maintain key customer relationships within the Department of Defense ecosystem. Contract retention is fundamentally positive as it indicates customer satisfaction and potentially creates opportunities for adjacent work.
While this specific contract won't materially move the needle on Parsons' financial performance, it reinforces their established presence in an essential defense capability area. The company's broader strategy appears focused on positioning in specialized technical domains where competition may be more and margins potentially more favorable than in commoditized services.
CHANTILLY, Va., April 07, 2025 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that the company was awarded a biological defense research contract to advance the Naval Medical Research Command’s (NMRC) mission to defend against the threat of biological and chemical warfare. The
Under this contract, Parsons will continue to support NMRC’s Biological Defense Research Directorate (BDRD) in their efforts to facilitate biological research for the rapid detection of infectious diseases of Department of Defense importance and the enhancement of global disease surveillance for early pathogen detection and response.
“At Parsons, our team of world-class scientists combined with our industry-leading biodefense capabilities play a pivotal role in advancing the federal government’s efforts to counter biological threats,” said Jon Moretta, President, Engineered Systems, for Parsons. “We look forward to continuing this critical work with the Naval Medical Research Command in defending U.S. military personnel stationed around the world from threats to their health and safety.”
Parsons has performed this work since 2018, providing NMRC with scientists who are subject matter experts in molecular biology, immunology, serology, bacteriology, laboratory science and management, field collection, field lab detection, outbreak response, production of reagents, and assay development. The company offers a full spectrum of biodefense services, including risk assessments; biological threat detection, identification, and surveillance; incident response and management; and technical expertise on issues impacting biosecurity.
To learn more about Parsons’ biodefense solutions, visit Parsons.com/health-and-biosciences/.
About Parsons:
Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and intelligence, space and missile defense, transportation, environmental remediation, urban development, and critical infrastructure. Please visit parsons.com and follow us on LinkedIn and Facebook to learn how we're making an impact.
Forward-Looking Statements:
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs and assumptions, and are not guarantees of future performance. Forward-looking statements are inherently subject to uncertainties, risks, changes in circumstances, trends and factors that are difficult to predict, many of which are outside of our control. Accordingly, actual performance, results and events may vary materially from those indicated in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future performance, results or events. Numerous factors could cause actual future performance, results and events to differ materially from those indicated in the forward-looking statements, including, among others: any issue that compromises our relationships with the U.S. federal government or its agencies or other state, local or foreign governments or agencies; any issues that damage our professional reputation; changes in governmental priorities that shift expenditures away from agencies or programs that we support; our dependence on long-term government contracts, which are subject to the government’s budgetary approval process; the size of our addressable markets and the amount of government spending on private contractors; failure by us or our employees to obtain and maintain necessary security clearances or certifications; failure to comply with numerous laws and regulations; changes in government procurement, contract or other practices or the adoption by governments of new laws, rules, regulations and programs in a manner adverse to us; the termination or nonrenewal of our government contracts, particularly our contracts with the U.S. federal government; our ability to compete effectively in the competitive bidding process and delays, contract terminations or cancellations caused by competitors’ protests of major contract awards received by us; our ability to generate revenue under certain of our contracts; any inability to attract, train or retain employees with the requisite skills, experience and security clearances; the loss of members of senior management or failure to develop new leaders; misconduct or other improper activities from our employees or subcontractors; our ability to realize the full value of our backlog and the timing of our receipt of revenue under contracts included in backlog; changes in the mix of our contracts and our ability to accurately estimate or otherwise recover expenses, time and resources for our contracts; changes in estimates used in recognizing revenue; internal system or service failures and security breaches; and inherent uncertainties and potential adverse developments in legal proceedings, including litigation, audits, reviews and investigations, which may result in materially adverse judgments, settlements or other unfavorable outcomes. These factors are not exhaustive and additional factors could adversely affect our business and financial performance. For a discussion of additional factors that could materially adversely affect our business and financial performance, see the factors included under the caption “Risk Factors” in our Registration Statement on Form S-1 and our other filings with the Securities and Exchange Commission. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. We assume no obligation to update any forward-looking statement made in this presentation that becomes untrue because of subsequent events, new information or otherwise, except to the extent we are required to do so in connection with our ongoing requirements under federal securities laws.
Media Contact:
Jonathan Larry
+1 706.832.7330
jonathan.larry@parsons.com
Investor Relations Contact:
Dave Spille
+1 703.775.6191
Dave.Spille@parsons.us
FAQ
What is the value of Parsons' (PSN) new Naval Medical Research Command contract?
What services will Parsons (PSN) provide under the NMRC biodefense contract?
How long has Parsons (PSN) been working with the Naval Medical Research Command?
What is the duration of Parsons' (PSN) new NMRC contract?
